• Explore /
  • Poster
  • / Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H.

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H.

Abstract Video & Slides Poster

Authors

null

Peter H. O'Donnell

University of Chicago, Chicago, IL

Peter H. O'Donnell , Christopher J. Hoimes , Jonathan E. Rosenberg , Daniel P. Petrylak , Nataliya Mar , Pedro C. Barata , Sandy Srinivas , Theodore Stewart Gourdin , Elizabeth Henry , Mehmet Asim Bilen , Saby George , Santosh Rao , Vasileios J. Assikis , Earle F Burgess , Brian E. Lewis , I. Alex Bowman , Sam Joseph Brancato , Shirly Mildiner-Earley , Yalin Zhu , Thomas W. Flaig

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03288545

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4564)

DOI

10.1200/JCO.2024.42.16_suppl.4564

Abstract #

4564

Poster Bd #

259

Abstract Disclosures

Similar Posters

First Author: Thomas W. Flaig

First Author: Daniel P. Petrylak

First Author: Christopher J. Hoimes

First Author: Evangelia Vlachou